NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care and pharmacy services, today announced it is now offering Novo Nordisk’s Wegovy ® (semaglutide) pill – the first and only FDA-approved oral GLP-1 therapy for chronic weight management and cardiovascular health – through its end-to-end telehealth platform. Eligible patients can access the Wegovy® pill for as little as $149 per month, further expanding LifeMD’s portfolio of branded obesity treatments.

This announcement broadens LifeMD’s long-standing collaboration with Novo Nordisk. As part of the relationship, LifeMD is featured on the NovoCare ® and Wegovy ® websites as a trusted telehealth provider, reflecting growing demand for convenient, clinically supported access to branded GLP-1 therapies.

On December 22, 2025, the U.S. Food and Drug Administration (FDA) approved Novo Nordisk’s Wegovy ® pill as the first and only oral GLP-1 therapy indicated to reduce excess body weight, support long-term weight maintenance, and reduce the risk of certain major adverse cardiovascular events. 1 FDA approval of the Wegovy ® pill was supported by a 64-week Phase 3 trial showing weight loss efficacy unmatched by other oral GLP-1 candidates, with once-daily treatment plus diet and exercise achieving 16.6% mean weight loss versus 2.7% with placebo. 2 The availability of an oral formulation is expected to broaden access to GLP‑1 treatment by offering an alternative option for patients who may be hesitant to initiate or continue weekly injections.

“In close collaboration with Novo Nordisk, we moved quickly to bring the Wegovy ® pill to patients through LifeMD at the attractive cash-pay price, reinforcing our role as a preferred virtual destination for evidence-based medical weight management,” said Justin Schreiber, Chairman and Chief Executive Officer of LifeMD. “We believe oral GLP-1 therapies represent an important next phase in obesity care. By supporting patients seeking care through Novo’s ‘Find a Doctor’ feature – alongside our own strong patient acquisition capabilities – we see a substantial long-term opportunity to further expand access and deliver a seamless experience that combines comprehensive clinical support with branded GLP-1 therapies shipped directly to patients’ homes.”

LifeMD’s integration with NovoCare ® Pharmacy provides streamlined access to Novo Nordisk’s FDA-approved GLP-1 medications, including Wegovy ® (injectable and oral) and Ozempic ® , at competitive cash-pay pricing. Patients receive a comprehensive, end-to-end experience that includes virtual visits with LifeMD’s affiliated medical group across all 50 states, ongoing clinical oversight, access to nationwide diagnostic testing, coordinated pharmacy fulfillment with fast shipping and real-time tracking, and simplified billing and payment.

“Innovation can only make a difference when people can access it. Our collaboration with LifeMD gives patients a trusted telehealth option where they can connect with a healthcare provider and begin authentic, FDA-approved treatment,” said Dave Moore, Executive Vice President, U.S. Operations, Novo Nordisk. “It’s another way we’re meeting people where they receive care and with the first and only FDA-approved oral GLP-1, Wegovy ® pill offers patients convenience and choice.”

All doses of the Wegovy ® pill are available by prescription to eligible LifeMD patients who are uninsured or whose insurance does not cover prescription weight-loss medications. Wegovy ® 1.5mg and 4mg pills are available to patients at $149 per month. After April 15, 2026, Wegovy ® 4mg pills will be available at $199 per month, and the 9mg and 25mg pills will be available at $299 per month.

1 Wegovy prescribing information: https://www.novo-pi.com/wegovy.pdf
2 Based on the trial product estimand: estimated efficacy in an idealized scenario in which all patients stayed on treatment and took no other weight loss therapies. Wharton S, Lingvay I, Bogdanski P, et al. Oral semaglutide 25 mg in adults with overweight or obesity. N Engl J Med. 2025; 393:1077-1087. DOI: 10.1056/NEJMoa2500969.

About LifeMD, Inc.

LifeMD ® is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy services, and specialized treatment across more than 200 conditions, including primary care, men’s and women’s health, weight management, and hormone therapy. The Company leverages a vertically integrated, proprietary digital care platform, a 50-state affiliated medical group, a state-of-the-art affiliated compounding pharmacy, and a U.S.-based patient care center to increase access to high-quality and affordable care. For more information, please visit LifeMD.com .

Cautionary Note Regarding Forward Looking Statements

This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended; Section 21E of the Securities Exchange Act of 1934, as amended; and the safe harbor provision of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this news release may be identified by the use of words such as: “believe,” “expect,” “anticipate,” “project,” “should,” “plan,” “will,” “may,” “intend,” “estimate,” “predict,” “continue,” and “potential,” or, in each case, their negative or other variations or comparable terminology referencing future periods. Examples of forward-looking statements include, but are not limited to, statements regarding our financial outlook and guidance, short and long-term business performance and operations, future revenues and earnings, regulatory developments, legal events or outcomes, ability to comply with complex and evolving regulations, market conditions and trends, new or expanded products and offerings, growth strategies, underlying assumptions, and the effects of any of the foregoing on our future results of operations or financial condition.

Forward-looking statements are not historical facts and are not assurances of future performance. Rather, these statements are based on our current expectations, beliefs, and assumptions regarding future plans and strategies, projections, anticipated and unanticipated events and trends, the economy, and other future conditions, including the impact of any of the aforementioned on our future business. As forward-looking statements relate to the future, they are subject to inherent risk, uncertainties, and changes in circumstances and assumptions that are difficult to predict, including some of which are out of our control. Consequently, our actual results, performance, and financial condition may differ materially from those indicated in the forward-looking statements. These risks and uncertainties include, but are not limited to, “Risk Factors” identified in our filings with the Securities and Exchange Commission, including, but not limited to, our most recently filed Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and any amendments thereto. Even if our actual results, performance, or financial condition are consistent with forward-looking statements contained in such filings, they may not be indicative of our actual results, performance, or financial condition in subsequent periods.

Any forward-looking statement made in the news release is based on information currently available to us as of the date on which this release is made. We undertake no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, except as may be required under applicable law or regulation.

Investor Contact:
Marc Benathen, Chief Financial Officer
[email protected]

Media Contact:
Jessica Friedeman, Chief Marketing and Product Officer
[email protected]